MannKind is trading 5.19% lower at $3.24 on October 9, 2026, with no clearly reported event today explaining the decline. - The latest company-specific item found was Truist’s October 7 decision to maintain its Buy rating while lowering its price target from $6 to $5; available sources do not directly link it to today’s move. - The biotech sector rallied, with XBI up about 2.5%, and the supplied broad-market indices were also higher.